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Amyotrophic lateral sclerosis is a progressive and devastating neurodegenerative disease. Despite 
decades of clinical trials, effective disease modifying drugs remain scarce. To understand the 
challenges of trial design and delivery, we performed a systematic review of phase II, phase II/III and 
phase III amyotrophic lateral sclerosis clinical drug trials on trial registries and PubMed between 2008 
and 2019. We identified 125 trials, investigating 76 drugs and recruiting more than 15000 people with 
amyotrophic lateral sclerosis. 90% of trials used traditional fixed designs. The limitations in 
understanding of disease biology, outcome measures, resources and barriers to trial participation in a 
rapidly progressive, disabling and heterogenous disease hindered timely and definitive evaluation of 
drugs in two-arm trials. Innovative trial designs, especially adaptive platform trials may offer 
significant efficiency gains to this end. We propose a flexible and scalable multi-arm, multi-stage trial 
platform where opportunities to participate in a clinical trial can become the default for people with 
amyotrophic lateral sclerosis.
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Abbreviations:
ALS: Amyotrophic lateral sclerosis
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised
CAFS: Combined Assessment of Function and Survival
CARE-MND: Clinical Audit Research Evaluation for motor neurone disease
CTIMP: Clinical Trial of Investigational Medicinal Product
ENCALS: European Network for the Cure of ALS
EMA: European Medicines Agency
EU: European Union
EU CTR: European Union Clinical Trial Registry
FDA: Food and Drug Administration
HR: Hazard ratio
ICTRP: International Clinical Trial Registry Platform
IMP: Investigational Medicinal Product
IQR: Interquartile range
MAMS: Multi-arm multi-stage
MND-SMART: Motor Neurone Disease – Systematic Multi-Arm Adaptive Randomised Trial
PLS: Primary lateral sclerosis
PMA: Progressive muscular atrophy
PROACT: Pooled Resources Open-Access ALS Clinical Trials
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
pwALS: people with ALS
RCT: Randomised controlled trial
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug 
Efficacy
TRICALS: Treatment and Research Initiative to Cure ALS 
UK: United Kingdom
US: United States
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Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with a median survival of 2-3 
years.1 While there has been some progress in non-pharmacological interventions such as non-
invasive ventilation and gastrostomy, and symptomatic pharmacological treatments in ALS,2 trials in 
the last 25 years have largely failed to identify effective disease-modifying drugs. Riluzole, approved 
in 1995, is the only globally licensed disease-modifying drug and prolongs survival by just 2-3 
months on average.3 Edaravone has been approved in some countries including United States, 
Canada, Japan and South Korea following a positive trial in a highly selected population.4 AMX0035 
(sodium phenylbutyrate-Taursodiol), masitinib and methylcobalamin have recently emerged as 
promising candidates following trials in subsets of people with ALS (pwALS).5-8 However, evidence 
for generalisable and substantial effects on survival for edaravone, AMX0035, masitinib and 
methylcobalamin is limited. 
Limitations of preclinical models and incomplete knowledge of the underlying biology of ALS are 
some of the factors hindering translational success.9 However, the last decade has seen substantial 
progress in our understanding of the genetic and molecular pathobiology of ALS and related 
disorders. This improved mechanistic insight has, in turn, led to the identification of many promising 
therapeutic targets that justify not only further experimental study but also, in many instances, formal 
clinical trials. Given that at present only a small fraction of pwALS participate in clinical trials,10 
despite a prognosis similar to that for many cancers where trial participation rates are considerably 
higher,11 there is an opportunity to learn from innovations in cancer medicine. This includes re-
thinking historical approaches to drug selection and evaluation in standalone two-arm trials.
Here, we evaluate previous trial designs and consider specific methodological challenges. These 
include the rapid pace of decline and accumulating disability in ALS, the clinically heterogeneous 
nature of ALS and a range of trial design and conduct issues. We review emerging innovative trial 
designs and propose a flexible multi-arm, multi-stage trial platform model that can incorporate new 
candidate drugs as they are identified.
Methods
We conducted a systematic search of trial registries including clinicaltrials.gov,12 World Health 
Organisation International Clinical Trials Registry Platform (ICTRP),13 European Union Clinical 
Trials Register (EU CTR),14 and PubMed on 9 April 2019 to identify Phase II, Phase II/III and Phase 
III Clinical Trials of an Investigational Medicinal Product (CTIMPs) assessing potential disease 
modifying drugs in ALS. We searched clinicaltrials.gov for all interventional trials of “amyotrophic 
lateral sclerosis” or “motor neuron disease”. We searched ICTRP and EU CTR for interventional 
trials of “amyotrophic lateral sclerosis” using “Phase II” and “Phase III” filters. We searched PubMed 
for “(“motor neuron disease” OR “amyotrophic lateral sclerosis”) AND (Clinical Trial [ptyp])”. Trials 
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registered, completed or published between 1 January 2008 and 9 April 2019, excluding extension 
trials, were included. No language restrictions were applied.
Statistical analysis
We performed a narrative synthesis on all included trials to summarise trials according to phase, study 
status, study duration, number of participants, investigational medicinal products, eligibility criteria 
and primary outcome measures. For studies with entries on multiple registries, data from 
ClinicalTrials.gov was used as the primary data source. For studies registered on registries with 
results published in journals, publications were used as primary source of data. To review sample size 
considerations including recruitment and retention, we summarised trials for completed trials with 
efficacy-based primary outcome measures according to number of study arms, number of participants 
recruited, number of participants recruited per arm, withdrawal rates and reasons for withdrawal. 
Data availability statement
Data for this review are available in the Supplementary Materials.
Results
Characteristics of trials 
A total of 1152 records were identified (see PRISMA diagram in Figure 1): 344 were duplicates, and 
683 were excluded because they did not meet our eligibility criteria. 58 records on PubMed 
corresponded with trials identified from the registry search. In total, 125 trials, with a total of 15647 
participants, were identified and included in the analysis. Characteristics of these trials are 
summarised in Table 1. 73 trials were recorded as completed. Six of the 125 trials were terminated 
prior to planned completion: two of these were trials with novel designs terminated for futility15,16; 
one was terminated due to adverse events17; one was terminated after a participant had rapid 
progression18; the reasons for termination for two studies were not stated. Trial duration ranged 
between 4 to 95 months (median 25 months).
Eligibility criteria
73% of trials specified ALS disease duration within their inclusion criteria. Median permitted 
maximum disease duration was 36 months (IQR 24-36 months). ALS participants at King’s stage 4 
(requiring enteral and/or respiratory support) were excluded from 119 trials. 53 trials stipulated use of 
riluzole as part of their inclusion or exclusion criteria.
Investigational Medicinal Products
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76 investigational medicinal products (IMPs) were evaluated in these 125 trials (Error! Reference 
source not found. and Error! Reference source not found.), of which ten IMPs were tested in three 
or more trials. The most frequently tested intervention was lithium, tested in ten trials (six Phase II, 
two Phase II/III, and two Phase III), involving a total of 1414 pwALS. 82 trials used oral forms of 
IMPs, but only seven of these specified forms such as liquid, soluble and powder preparations which 
could be delivered through enteral feeding tubes, an important consideration raised in engagement 
with pwALS. Two IMPs have been licensed since riluzole was approved in the United States (US) in 
1995 and the European Union in 1996. Edaravone was licensed in Japan in 2015 and in the US in 
2017 after a study showed improvement in the Amyotrophic Lateral Sclerosis Functional Rating Scale 
Revised (ALSFRS-R, a multi-domain functional rating scale) in a small subset of pwALS 
characterised by early ALS, functional independence with no respiratory insufficiency and a decrease 
in ALSFRS-R of 1 to 4 points during a 12-week observation period.4  However, in the European 
Union, Mitsubishi Tanabe Pharma GmBH withdrew their application for marketing authorisation for 
edaravone after the European Medicines Agency (EMA) cited concerns on the strength of evidence 
for efficacy. Areas flagged included: to establish if the decrease in ALSFRS-R is considered clinically 
relevant in the context of evidence from other studies, generalisability of results to a European 
population, and the need to provide confirmatory efficacy data on survival and survival-based 
endpoints such as tracheostomy and non-invasive ventilation.19 A previous trial with broader 
inclusion criteria and a trial of participants with more severe disease had not shown evidence of 
efficacy.20,21 A subsequent, retrospective single-centre analysis suggests improved survival in pwALS 
treated with edaravone compared with a historical control group.22 Conversely, edavarone did not 
significantly improve survival in a multicentre Italian observational study23 or in a surveillance 
evaluation by the US Department of Veterans Affairs.24 
Masitinib in combination with riluzole reduced progression of ALSFRS-R in “normal progressors” in 
a Phase II/III study7 compared to riluzole with placebo, leading to orphan drug designation being 
granted in Europe and the US. However, EMA refused marketing authorisation for masitinib, based 
on lack of reliable evidence of its benefits, citing concerns on patient stratification leading to loss of 
generalisability, aspects of study conduct and the handling of missing data.25
More recently, FDA and EMA have granted orphan drug designation for AMX0035 (sodium 
phenylbutyrate-Taursodiol) following a positive phase II trial6 in which AMX0035 reduced rate of 
decline of ALSFRS-R by 0.42 points/month over 24 weeks compared to placebo. Although there was 
no difference in survival between treatment groups during the primary analysis, subsequent analysis 
of long-term open label extension results showed a significant improvement in survival (HR=0.56, p= 
0.023) in participants originally randomised to AMX0035 compared to participants originally 
randomised to placebo.5 However, it is notable that overall sample size was small, only 20% of 
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participants remained in the extension trial at the time of publication, and the cohort was highly 
enriched using strict eligibility criteria and thus, treatment effect may not be generalisable to the wider 
ALS population. In April 2021, FDA expressed an interest in seeing data from an additional placebo-
controlled trial prior to receiving a New Drug Application for AMX0035.26
In a post hoc-analysis of a long-term phase II/III randomised controlled study, ultra-high-dose 
methylcobalamin treated pwALS prolonged time to death or ventilation support and reduced decrease 
in ALSFRS-R score compared to placebo for pwALS diagnosed and entered into trial within 12 
months of symptom duration.8 However, the primary analysis for the trial did not show any 
significant difference between treatment groups.8
Nuedexta (dextromethorphan / quinidine) was approved for treatment of pseudobulbar affect in ALS 
in 2011 by the FDA and 2013 by EMA. Following reports from pwALS noting an improvement of 
their bulbar symptoms on Nuedexta, a phase II randomised, blinded, crossover study of 60 
participants was performed. Nuedexta was associated with significantly improvement in the Center 
for Neurologic Study Bulbar Function Scale (CNS-BFS), a self-reported measure of swallowing, 
salivation and speech, compared to placebo over a treatment period of 28 to 30 days.27 However, it is 
unclear if this reduction translates into a clinically meaningful effect. Longer term larger studies are 
required to establish its effects on disease progression. Of note, the marketing authorisation for 
Nuedexta has been withdrawn in the EU on request of the manufacturer due to commercial reasons. 
 
Trial design
90% of the included trials used traditional fixed designs where each trial evaluated one active IMP 
(including dose-ranging studies testing one active IMP at multiple doses) and were designed, 
conducted then analysed in a consecutive manner, with no flexibility to adopt changes which may 
become desirable over the course of the trial. 12 trials used ‘novel’ or ‘alternative’ trial designs (Table 
2). In the Airlie House ALS clinical trial guidelines,28 such designs include adaptive studies, seamless 
Phase II/III designs, enrichment designs and futility designs.
Next, we reviewed sample size considerations including recruitment and retention. To do this, we 
analysed studies with efficacy-based primary outcome measures (Table 3). Results were available for 
49 (32 Phase II, 5 Phase II/III, 12 Phase III) of the 89 trials with efficacy-based primary outcome 
measures. 37 studies evaluated two arms, five were single-arm (including one using historical 
controls29), six trials evaluated three arms (five studies of one IMP each at different doses and one 
multi-arm trial of two active IMPs) and a single trial had four arms (testing one IMP at three doses 
against placebo). The total number of participants recruited per trial ranged from 23 to 943. The 
median number of participants per arm was 43 (IQR 23-107) (Figure 2). 26 of 49 trials (20 Phase II, 
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four Phase II/III, two Phase III) recruited fewer than 100 participants in total, and only four Phase III 
trials recruited more than 500 participants. Excluding trials with adaptive designs which were 
terminated early, 87% of the studies achieved at least 90% of their target enrolment. However, 
attrition significantly affected studies: 40% of trials had an attrition rate (calculated as the proportion 
of recruited patients who did not complete studies for reasons other than death) of more than 20% 
(range 0-70%, median 16%). In these studies, median percentage of participants withdrawing due to 
adverse events was 26% (IQR 0-45%, range 0-100%). Other reasons for withdrawal included 
participant request, protocol violation, loss to follow up, perceived lack of efficacy, non-compliance, 
disease progression felt to be due to study drug, burden of participating, physician or investigator’s 
decision, and reaching protocol-defined stopping point other than death.
Outcome measures
24 of the 49 studies used ALSFRS-R, while ten trials used survival, and two used compound scores 
combining survival and ALSFRS-R as primary outcome measures.30,31 Other primary outcome 
measures included alternative functional rating scales, muscle strength testing, disease staging, 
respiratory function and biofluid biomarkers (Table 3). The substantial variation in primary endpoints 
used reflects the lack of consensus on what is considered a relevant and clinically important 
improvement for confirmatory trials, and the lack of sensitive and reliable outcome measures to detect 
potential treatment effects in exploratory trials.
ALSFRS-R scores were reported as mean rate of decline or slope of decline, or as an absolute or 
percentage change from baseline score, measured over durations ranging between eight to 90 weeks. 
Trials using ALSFRS-R were planned to detect a range of treatment effects, including a reduction in 
the rate of decline of anything from 10 to 50%, or a 3-point difference in ALSFRS-R scores over 24 
weeks to 40 weeks.
Survival results were reported in several ways including number of deaths, proportion alive at a 
specified timepoint, Kaplan-Meier curves, time-to-event including death, or proxies for survival such 
as tracheostomy or the initiation of permanent assisted ventilation. Follow up periods for survival 
ranged from 12 to 18 months.
Biomarkers were specified as outcome measures in 42 (34%) of trials: 27 trials included biofluid 
biomarkers, three measured imaging biomarkers and 13 measured neurophysiological biomarkers. 
Proportion of pwALS in clinical trials
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To determine the approximate proportion of pwALS participating in clinical trials, we evaluated 
reported recruitment data for trials identified in our systematic search and compared this to ALS 
epidemiology data (Error! Reference source not found.). We identified 66 studies which recruited 
in the United Kingdom (UK) and the US and extracted the total number of participants from these 
countries. This was based on published data where these were available; and where not, by taking the 
proportion of recruiting centres in the UK or US multiplied by the total number of participants. 
Applying this approach to those studies where the country of recruitment was known gave estimated 
recruitment within 1% (2887 v 2916 observed) of the true value. We calculated trial participation 
rates using an estimated annual incidence of ALS of 2/100,00032 and population data from national 
statistics. We estimate that fewer than 5% of pwALS in the UK and 8% of pwALS in the US 
participated in a CTIMP during this period. Globally, we estimate that the 15647 pwALS who 
participated in these 125 CTIMPs between 2008 and 2019 represent around 2.5% of the total number 
of new cases of ALS during this period.
Discussion
Our analysis of trials between 2008 and 2019 found 76 IMPs evaluated in 125 trials, predominantly 
with two-arm trial designs with a range of sample sizes and a variety of outcome measures. We 
estimate that fewer than 5% of newly diagnosed pwALS entered a clinical trial. Limitations of this 
review include incomplete reporting of completed trials, which may reflect reporting bias. 73 trials 
were recorded as completed, but for 12 the results were not available in a manner consistent with 
European Union (EU) or Food and Drug Administration (FDA) regulations. Of these 12, two did not 
provide completion dates, two were completed within the preceding 12 months and eight were 
completed more than 12 months prior, noting that FDA and EU regulations mandate reporting of 
results within 12 months of completion. Three of these trials published results in either journals or on 
trial registries between April 2019 at the time of writing,7,33,34 while three had published conference 
proceedings but these did not contain the full dataset required by regulations. Furthermore, there was 
inconsistency of data across data sources for a few trials, where conflicting data was recorded on 
different trial registries or in trial publications. For our review, we analysed data from the primary 
source as specified in our methods. Ideally, we would group studies according to their aims for our 
analysis. We would divide studies into exploratory vs confirmatory studies and subdivide exploratory 
studies according to their main aims including safety, dose-ranging, or efficacy. However, most trial 
registries do not currently include such information. Thus, we limited our analysis to phase II and 
phase III studies, using the primary outcome measure presented to infer the primary aim of each 
study. 
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Here, we discuss challenges in designing, delivering and conducting trials in ALS, and review the 
possible causes of low proportion of pwALS entering CTIMPs.
Understanding of disease biology
While our understanding of ALS disease biology, especially in genetics and molecular biology, has 
improved over recent years, there remains significant gaps in our knowledge of mechanistic targets 
and networks in ALS.9 This impedes improvements in disease models, drug development and 
selection for clinical trials.9,35 Furthermore, the limitations in disease understanding also poses 
challenges in developing more reliable, objective, sensitive and specific biomarkers of disease 
progression and prognostication. Notwithstanding recent advances in biomarker development, these 
are yet to be established and validated as primary efficacy-based outcome measures in clinical trials.36 
Thus, we continue to rely on clinical rating scales and survival to evaluate efficacy and narrow 
inclusion criteria to reduce heterogeneity in trial cohorts. This, in turn, has implications on sample 
sizes, trial duration, access to trials and generalisability of results as discussed further below. 
Disease-related factors 
Heterogeneity of clinical presentation, site of onset and rate of progression often result in diagnostic 
delay, with an average time from symptom onset to diagnosis of 12-15 months.37 Combined with the 
multiple manifestations, rapidly progressing, disabling and short survival of the disease, this results in 
a short time-window to identify, screen and recruit pwALS. Furthermore, adherence with trial 
protocols often becomes challenging with increasing disability; movement, ambulation, speech, 
swallowing and respiration are commonly affected, the latter causing some pwALS to become 
dependent on enteral feeding and ventilatory support. Data from Clinical Audit Research Evaluation 
for Motor Neurone Disease (CARE-MND),38 the highly curated Scottish MND register, showed that a 
quarter of pwALS in Scotland between 2015 and 2019 had a gastrostomy and 17% used non-invasive 
ventilation. This is particularly problematic for trials where invasive procedures, such as intrathecal 
delivery of IMPs or lumbar punctures, or maintained ability to swallow oral medications are required. 
Distant travel to trial centres to attend face-to-face appointments is likely to be physically demanding 
and burdensome for pwALS with accumulating disability. Cognitive and behavioural changes are 
well recognised and worsen with disease progression,39-41 forming another barrier to trial 
participation, including issues around informed consent, and retention.
Narrow versus broad trial inclusion criteria
In addition to practical and logistical considerations, phenotypic heterogeneity in ALS adds 
complexity to participant selection. This includes variation in survival which is well recognised in 
ALS.42-45 In a Scottish cohort (2015-2016), approximately 10% pwALS are long survivors, defined as 
survival beyond 8 years, with median survival from onset of 15.6 years.42 Other sources of 
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heterogeneity with prognostic implications include age at onset, site of presentation, respiratory 
involvement, subtypes of ALS, genetic heterogeneity and diagnostic certainty.1 
To create a more homogenous cohort, increase trial protocol adherence and exclude long survivors, 
investigators often use restricted eligibility criteria as demonstrated in our review as well as a review 
of ALS clinical trials between 2000 and 2017 by van Eijk et al.10 However, employing strict eligibility 
criteria inevitably affects the generalisability of results. Furthermore, it reduces the proportion of 
eligible participants in a condition where prognosis is grave and treatment options are severely 
limited. Van Eijk et al.10 found that on average 60% of pwALS were ineligible to participate in 
clinical trials, with more than 20% of pwALS excluded because of El Escorial criteria stipulations 
alone. Along with restrictions of symptom/disease duration, this has particular implications on 
recruitment of patients of certain phenotypes46 such as progressive bulbar palsy, flail arm or flail leg 
syndrome, primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA). Notably, the 
complexity and poor test-retest reliability of the revised El Escorial criteria has been highlighted in a 
recent study,47 leading to the proposal of the Gold Coast criteria48 where diagnostic criteria for ALS is 
simplified and the categories of possible, probable and definite ALS in the El Escorial criteria 
collapsed into a single entity. In our review, 95% of trials excluded pwALS who were enterally or 
ventilator supported while 42% either mandate riluzole co-treatment or exclude pwALS on 
concomitant riluzole. Of note, 45% pwALS in Scotland were started on riluzole between 2015 and 
2020, 15% of whom subsequently discontinued riluzole.49 Indeed when applying the eligibility 
criteria of the edaravone 2017 trial4 to an incident cohort, only 10% pwALS would have been 
eligible.10 Nevertheless, the authors found that strict eligibility criteria only minimally reduced 
heterogeneity in trial endpoints.10 
An alternative approach is to adopt broad inclusion criteria recruiting all subtypes of ALS including 
long survivors, supported by protocol innovations to allow participation of pwALS with more 
advanced disease. Examples include liquid IMP preparations and home/telephone/video 
assessments.50 However, this approach requires larger sample sizes to enable a sufficiently powered 
trial to account for a potentially reduced effect size in a more heterogeneous cohort, or a prospective 
analysis plan that excludes ALSFRS-R (but not survival) data, from participants who are beyond 8 
years of disease onset at trial entry.
  
The recent development of personalised risk prediction models,1,45 based on clinical and genetic data, 
including the presence of a C9orf72 repeat expansion, could be used for stratification in future trials 
and might achieve a better balance between endpoint heterogeneity and exclusion rates. Van Eijk et 
al10 calculated that incorporating the European Network for the Cure of ALS (ENCALS) risk model1 
Page 15 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
14
for participant selection in the edaravone 2017 trial4 could increase proportion of pwALS eligible 
nearly fivefold while maintaining similar power.
Designing clinical trials to evaluate clinically meaningful change
The tension between practical considerations of feasibility of recruitment, compliance and retention, 
versus adequate power for evaluation of meaningful outcome measures is apparent throughout the 
ALS trial literature. Indeed, what constitutes a clinically meaningful change on these endpoints is 
difficult to define. The range of primary outcome measures and primary endpoints reflects the 
absence of widely available, robust and sensitive biomarkers. There is, however, an encouraging trend 
towards the use and development of biomarkers in more recent trials. Out of 29 trials including 
biomarkers as outcome measures with trial start dates available in registries, 21 (72%) were 
conducted within the past 5 years. Meanwhile, there remains a dependency on clinical ordinal scales, 
in particular the ALSFRS-R. ALSFRS-R was the most common primary outcome measure used (41% 
of Phase II studies and 35% of Phase III studies). Survival was the second most common primary 
outcome measure used in Phase III studies (30%). 
Although ALSFRS-R is widely used and validated, a Rasch analysis identified that ALSFRS-R total 
score lacks unidimensionality, meaning investigators cannot be confident that the same total 
ALSFRS-R score in two pwALS reflects comparable clinical conditions.51,52 The use of total 
ALSFRS-R score is particularly problematic where differences in treatment responses between 
subscales increase and may dilute treatment effects.53 Furthermore, as ALSFRS-R plateaus and small 
reversals are common, stable ALSFRS-R scores over short intervals may not represent treatment 
effect and has implications for trial duration.54  Notwithstanding these issues, the sample size required 
to detect a clinically meaningful change in ALSFRS-R55 is considerable. Using simulation models 
based on the Pooled Resources Open-Access ALS Clinical Trials (PROACT) database56 we calculate 
that approximately 200 participants (100/arm) are required for a two-arm randomised controlled trial 
(RCT) with randomisation of 1:1, to provide 85% power to detect a 25% difference in rate of 
ALSFRS-R decline over 12 months with a test conducted with a two-sided 20% significance level 
(Figure 3A). We believe this statistically liberal approach is appropriate in Phase II. Similarly, noting 
that survival is considered the gold-standard outcome for Phase III and using natural history data 
obtained from CARE-MND,38 we estimate that >500 patients are required to evaluate one IMP in a 
two-arm RCT with randomisation of 1:1 and 2 years follow up, to achieve a power of 90% to detect a 
hazard ratio for death of 0.65 with a two-sided 5% significance level. A larger sample size would be 
required to account for the increased heterogeneity should trials use broader inclusion criteria.
These sample sizes demonstrate a major challenge in ALS trials. More than half of the studies in our 
review with efficacy-based primary outcome measures recruited fewer than 100 participants, 
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notwithstanding allowances for missing data, dropouts and death. Thus, with hindsight, these studies 
were highly unlikely to answer – in a statistically robust manner – whether the proposed intervention 
was clinically effective or warranted further evaluation in a Phase III trial. The inability to determine 
drug efficacy or futility in a single, definitive and timely trial, may lead to re-evaluation of the same 
IMP in subsequent trials. This is inefficient in time, cost and patient resource.
Regulatory variation across countries
Another important challenge in ALS trials is the variation in regulatory requirements and complex 
administrative processes across different countries and jurisdictions. These often hinder and delay 
multinational clinical trials as demonstrated in other diseases and may detract pharmaceutical 
companies from running trials in some countries.57,58 This is a particular challenge to conducting 
sufficiently powered, definitive trials in diseases like ALS where prevalence is low. Furthermore, as 
shown in the case of edaravone, regulatory authorities vary considerably in the level and extent of 
evidence for efficacy considered sufficient for drug approval. This reflects one of many ethical 
dilemmas in ALS clinical trial regulations. On one hand, regulatory bodies exist to protect and 
safeguard public health, and does so by ensuring that only drugs with acceptable efficacy and safety 
profiles are approved. On the other, pwALS have strongly advocated for access to treatments, stating 
that they are willing to accept greater risks that drugs are harmful or ineffective in the face of a fatal 
incurable illness.26 Indeed, more than 50000 people signed a petition by the ALS Association and I 
AM ALS to this effect, requesting that FDA make AMX0035 available based on the phase II trial 
results.59 Some argue that so called ‘real-world evidence’ from post-marketing observational studies 
can substitute for high quality evidence from large RCTs.60,61 While such observational studies are 
useful in detecting rare adverse events and (possibly) large, unexpected beneficial effects, the 
potential for such studies to determine moderate efficacy or safety signals accurately is limited by 
inherent biases.62 There are well established licencing pathways such as Fast Track (FDA) or PRIority 
MEdicine (PRIME – EMA) to accelerate evaluation of IMPs, and programmes such as expanded 
access (FDA), compassionate use (EMA) or Early Access to Medicines Scheme (UK) which allow 
access to IMPs for people with ALS who are unable to access these in the context of clinical trials. 
One strategy, therefore, would be for trialists to increase their probability of trial success by recruiting 
more homogenous cohorts through narrower inclusion criteria, with pwALS who do not meet these 
criteria able to access these drugs via expanded access programmes. However, regulators will usually 
only provide a marketing authorisation for the population in which the IMP has shown efficacy in 
randomised controlled trials. The processes through which ALS stakeholders (industry, trialists, 
clinicians and pwALS) navigate clinical development and regulatory approval is therefore complex, 
and much would be gained from harmonisation and increasing clarity and consistency in national trial 
regulations, their interpretation and implementation. The Organisation for Economic Co-operation 
and Development (OECD) have set out stratified recommendations to this end.63 
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Proposal for future trials
While efforts to harmonise national regulations are underway, considering the small proportion of 
pwALS entering interventional clinical trials and the increasing emergence of candidate medicines, 
there is an opportunity to improve trial design in ALS. This requires innovation in how drugs are 
selected and how trials are undertaken. The emerging trends in drug selection encompass four broad 
approaches; machine learning assisted systematic evaluation of the pre-clinical and clinical 
literature,64 phenotypic high-throughput drug screening platforms adopting human induced pluripotent 
stem cell modelling of brain cells,65,66 expert panel evaluation of candidate drugs, and more target led 
discovery of novel putative medicines. Moreover, the emergence of gene-based treatment approaches 
for monogenetic causes of ALS has already led to genetically stratified treatment trials that bring 
additional considerations including the nature of the control arm.67,68 Regardless of how drugs are 
selected, the pace of growth in both our biological understanding of ALS and linked new technologies 
for accelerated drug screening and discovery heralds an era where multiple biologically plausible 
putative medicines will be identified.
Innovative trial designs pioneered in cancer medicine69,70 and successfully adopted in a small number 
of ALS trials may offer a new standard. In our review, seven out of ten of these trials, where results 
were available, delivered conclusive answers on lack of efficacy of IMPs (Table 2). Five15,16,71-73 out 
of seven trials with adaptive designs and predefined stopping criteria were able to identify futile 
treatments and stop trials early, reducing exposure of pwALS to ineffective treatments. An adaptive 
multiphase approach in evaluating ceftriaxone enabled timely, seamless transition between phases, 
removing the need for multiple submissions for funding and regulatory approvals.74
Another class of trial design that offers promise for ALS is the platform trial. These are trials which 
evaluate multiple treatments simultaneously using a single master protocol, typically against a shared 
control or standard-of-care arm. Platform trials are especially effective where there are several 
promising medicines without any a priori evidence to favour one over the other.75,76 In this regard, 
such trials offer significant gains in efficiency by using a single master protocol as opposed to running 
multiple and inevitably consecutive conventional two-arm studies. Recently, such designs have 
enabled triallists to identify the efficacy of dexamethasone in COVID-19 at speed.77 Platform trials 
may include adaptive features, such as in Multi-arm Multi-stage (MAMS) platform trials (Figure 3B). 
In these, interim analyses are performed at pre-specified timepoints, with treatment arms being 
discontinued if they do not reach predetermined activity or safety outcomes. Seamless Phase II into III 
transition can also be prospectively incorporated into the trial protocol and activated if a given arm 
meets predefined criteria. With appropriate statistical approaches, it is possible to use outcome 
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information gathered from participants in Phase II in the Phase III part of the trial. Further new 
treatments can be introduced and tested within the protocol.
The time and cost efficiencies gained by stopping ineffective arms early, while being able to introduce 
new arms in what is in effect a continuous trial platform without initiating further independent RCTs, 
are significant. It is estimated that a multi-arm study evaluating two active arms within the same trial 
against control halves the cost of separate traditional two-arm RCTs to evaluate two drugs.76 The 
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy 
(STAMPEDE) trial is an example of a successful MAMS trial. Ten treatments have been evaluated 
over 20 years, resulting in change in standard-of-care three times.78-80 If standard two-arm RCTs had 
been used, it has been estimated that evaluating the same number of treatments would have required 
more than 40 years.78-80 Building on this success, similar adaptive trials have been initiated in 
melanoma, glioblastoma multiforme and Ebola.81
Notwithstanding the benefits of MAMS platform, they present significant operational and statistical 
challenges. One operational challenge is the need for substantial and sustained funding to enable the 
creation of an integrated and long-term administrative, project and statistical trial infrastructure.82-84 
Statistical analysis plans for MAMS can be complex and include the need to calculate the type I error, 
or the choice of stopping boundaries, on how to adjust boundaries when the variance of a normally 
distributed endpoint is unknown, on the impact of adding a treatment arm during a MAMS trial or on 
whether additional patients should be allocated to the control group in such circumstances.85-88 The 
organisation of interim analyses must also be efficient, with data collection, monitoring and statistical 
analysis undertaken against tight deadlines, particularly when aiming for a seamless transition from 
Phase II to Phase III.
Accordingly, the development of platform trials in ALS is gathering momentum with three declared 
initiatives: USA-based HEALEY ALS Platform Trial89 (ClinicalTrials.gov registration number 
NCT04297683), European-based Treatment and Research Initiative to Cure ALS (TRICALS) 
‘MAGNET’ platform trial68 and UK-based Motor Neurone Disease – Systematic Multi-Arm 
Randomised Trial90 (ClinicalTrials.gov registration number NCT04302870). Each will have a master 
protocol and is multi-arm, although they vary in terms of inclusion criteria, genetic stratification, 
selection method of IMPs and the use of trial adaptation. Specifically, the HEALEY trial is designed 
to evaluate multiple drugs under a master protocol with sharing of participants on placebo across 
treatment regimens and frequent interim analyses to allow early stopping for success or futility of 
individual regimens. Participants will be randomised firstly to a treatment regimen, followed by 3:1 
randomisation to either active treatment or placebo. Current listed arms are zilucoplan, verdiperstat 
and CNM-Au8. The MAGNET trial is a phase III adaptive platform trial which will use a 
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personalised prognostication model to determine eligibility. The first drug to be evaluated in 
MAGNET is lithium carbonate in UNC13A homozygous patients. MND-SMART is initially testing 
two IMPs (trazodone and memantine) against a single placebo arm with a seamless adaptive Phase II / 
Phase III multi-arm, multi-stage design, incorporating measures to maximise accessibility to pwALS 
including using broad inclusion criteria, liquid IMP and video/telephone assessments.
Conclusion
Phenotypic heterogeneity, disease-related disability and the lack of sensitive and reliable outcome 
measures are some of the challenges in designing and conducting ALS clinical trials. With improved 
understanding of ALS disease biology and increasing number of promising candidate medicines being 
identified for evaluation, innovative trial designs can be instrumental in making trials more efficient, 
flexible, scalable and accessible. Together these advances will bring closer a new default where every 
pwALS has the opportunity to participate in a clinical trial.
Acknowledgments
A.R.M. is a Lady Edith Wolfson Clinical Fellow and is jointly funded by the Medical Research 
Council (MRC) and the Motor Neurone Disease Association (MR/R001162/1).
Funding
This work is supported by the UK Dementia Research Institute, which receives its funding from UK 
DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's 
Research UK.
Competing interests
Macleod and Weir were members of the MHRA Commission for Human Medicines at the time that the 
mastinib application was declined by the EMA. Weir is an independent data monitoring committee 
member for clinical trials of AB Science (marketing authorisation holder for masitinib) for which 
University of Edinburgh receives payment. Weir and Parker were supported in this work by NHS 
Lothian via Edinburgh Clinical Trials Unit. In the last 3 years, Chataway has received support from the 
Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute 
for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme 
(NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in 
part by the National Institute for Health Research, University College London Hospitals, Biomedical 
Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by 
the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, 
Page 20 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
19
Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in 
advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, Novartis and 
Roche.
Page 21 of 35
https://mc.manuscriptcentral.com/braincom













































































1. Westeneng H-J, Debray TPA, Visser AE, et al. Prognosis for patients with 
amyotrophic lateral sclerosis: development and validation of a personalised prediction 
model. The Lancet Neurology. 2018;17(5):423-433.
2. Dorst J, Ludolph AC, Huebers A. Disease-modifying and symptomatic treatment of 
amyotrophic lateral sclerosis. Therapeutic Advances in Neurological Disorders. 
2017;11:1756285617734734.
3. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis 
(ALS)/motor neuron disease (MND). The Cochrane database of systematic reviews. 
2012(3):Cd001447.
4. The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. 
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral 
sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 
2017;16(7):505-512.
5. Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the 
CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral 
sclerosis. Muscle Nerve. 2021;63(1):31-39.
6. Paganoni S, Macklin EA, Hendrix S, et al. Trial of Sodium Phenylbutyrate-
Taurursodiol for Amyotrophic Lateral Sclerosis. The New England journal of 
medicine. 2020;383(10):919-930.
7. Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in 
patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic 
lateral sclerosis & frontotemporal degeneration. 2020;21(1-2):5-14.
8. Kaji R, Imai T, Iwasaki Y, et al. Ultra-high-dose methylcobalamin in amyotrophic 
lateral sclerosis: a long-term phase II/III randomised controlled study. Journal of 
Neurology, Neurosurgery &amp;amp; Psychiatry. 2019;90(4):451.
9. Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral 
sclerosis. Neuropharmacology. 2020;167:107986.
10. van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for 
amyotrophic lateral sclerosis clinical trials. Neurology. 2019.
11. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic Review 
and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient 
Barriers to Cancer Clinical Trial Participation. JNCI: Journal of the National Cancer 
Institute. 2019;111(3):245-255.
12. NIH US Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed.
13. World Health Organisation. International Clinical Trials Registry Platform. 
http://apps.who.int/trialsearch/. Accessed.
14. European Medicines Agency. EU Clinical Trials Register. 
https://www.clinicaltrialsregister.eu/. Accessed 9 April 2019.
15. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in 
combination with riluzole for treatment of amyotrophic lateral sclerosis: a 
randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 
2010;9(5):481-488.
16. Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-
controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral 
sclerosis. PloS one. 2012;7(6):e37885.
17. Meyer T, Maier A, Borisow N, et al. Thalidomide causes sinus bradycardia in ALS. 
Journal of neurology. 2008;255(4):587-591.
Page 22 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
21
18. Kasper J, Heesen C, Kopke S, Fulcher G, Geiger F. Patients' and observers' 
perceptions of involvement differ. Validation study on inter-relating measures for 
shared decision making. PLoSOne. 2011;6(10):e26255.
19. European Medicines Agency Committee for Medicinal Products for Human Use. 
Withdrawal assessment report: Radicava. In: European Medicines Agency Committee 
for Medicinal Products for Human Use, ed. EMA/CHMP/290284/2019. 
Amsterdam2019.
20. Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, 
placebo-controlled study of efficacy and safety of edaravone (MCI-186) in 
amyotrophic lateral sclerosis patients. Amyotrophic lateral sclerosis & frontotemporal 
degeneration. 2014;15(7-8):610-617.
21. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone 
(MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 
3, requiring assistance for eating, excretion or ambulation). Amyotrophic lateral 
sclerosis & frontotemporal degeneration. 2017;18(sup1):40-48.
22. Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects 
of edaravone on survival of patients with amyotrophic lateral sclerosis. 
eNeurologicalSci. 2018;11:11-14.
23. Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with 
edaravone in amyotrophic lateral sclerosis. Journal of neurology. 2020;267(11):3258-
3267.
24. Vu M, Tortorice K, Zacher J, et al. Assessment of Use and Safety of Edaravone for 
Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. JAMA 
Netw Open. 2020;3(10):e2014645.
25. European Medicines Agency. Refusal of the marketing authorisation for Alsitek 
(masitinib). 2018.
26. Amylyx. Amylyx Pharmaceuticals provides global regulatory update on AMX0035 
for ALS. https://www.amylyx.com/2021/04/14/amylyx-pharmaceuticals-provides-
global-regulatory-update-on-amx0035/. Published 2021. Accessed.
27. Smith R, Pioro E, Myers K, et al. Enhanced Bulbar Function in Amyotrophic Lateral 
Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017;14(3):762-772.
28. van den Berg LH, Sorenson E, Gronseth G, et al. Revised Airlie House consensus 
guidelines for design and implementation of ALS clinical trials. Neurology. 
2019;92(14):e1610-e1623.
29. Bedlack RS, Wicks P, Vaughan T, et al. Lunasin does not slow ALS progression: 
results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotrophic 
Lateral Sclerosis and Frontotemporal Degeneration. 2019;20(3-4):285-293.
30. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo 
for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-
blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059-1067.
31. Meininger V, Genge A, van den Berg LH, et al. Safety and efficacy of ozanezumab in 
patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-
controlled, phase 2 trial. Lancet Neurol. 2017;16(3):208-216.
32. Marin B, Boumédiene F, Logroscino G, et al. Variation in worldwide incidence of 
amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57-74.
33. ClinicalTrials.gov. Identifier NCT02450552 Clinical trial of ezogabine (retigabine) in 
ALS subjects. https://clinicaltrials.gov/ct2/show/NCT02450552. Accessed 3 February 
2020.
Page 23 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
22
34. Shefner JM, Cudkowicz ME, Hardiman O, et al. A phase III trial of tirasemtiv as a 
potential treatment for amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & 
frontotemporal degeneration. 2019;0(0):1-11.
35. Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, 
Mechanisms, and Therapeutics: Where Are We Now? Frontiers in Neuroscience. 
2019;13(1310).
36. Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in Motor Neuron Disease: A 
State of the Art Review. Front Neurol. 2019;10:291-291.
37. Donaghy C, Dick A, Hardiman O, Patterson V. Timeliness of diagnosis in motor 
neurone disease: a population-based study. The Ulster medical journal. 
2008;77(1):18-21.
38. Leighton D, Newton J, Colville S, et al. Clinical audit research and evaluation of 
motor neuron disease (CARE-MND): a national electronic platform for prospective, 
longitudinal monitoring of MND in Scotland. Amyotrophic lateral sclerosis & 
frontotemporal degeneration. 2019:1-9.
39. Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior 
changes associated with advancing disease stage in ALS. Neurology. 
2018;91(15):e1370-e1380.
40. Radakovic R, Abrahams S. Multidimensional apathy: evidence from 
neurodegenerative disease. Current Opinion in Behavioral Sciences. 2018;22:42-49.
41. Beswick E, Park E, Wong C, et al. A systematic review of neuropsychiatric and 
cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. Journal 
of neurology. 2020.
42. Leighton DN, J.; Parry, D.; Cleary, E.; Colville, S.; Stephenson, L.; Davenport, R.; 
Morrison, I.; Swingler, R.; Deary, I.; Porteous, M.; Aitman, T.; Gorrie, G.; Chandran, 
S.; Pal, S. Phenotype-genotype characterisation of ‘long survivors’ with motor 
neurone disease in Scotland. Paper presented at: Amyotroph Lateral Scler 
Frontotemporal Degener2018.
43. Pupillo E, Messina P, Logroscino G, Beghi E, the SG. Long-term survival in 
amyotrophic lateral sclerosis: A population-based study. Annals of neurology. 
2014;75(2):287-297.
44. Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS 
in Olmsted County, 1925-2004. Journal of neurology, neurosurgery, and psychiatry. 
2010;81(10):1144-1146.
45. Goyal NA, Berry JD, Windebank A, et al. Addressing Heterogeneity in Als Clinical 
Trials. Muscle & Nerve. 2020;n/a(n/a).
46. Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria - 2015. 
Amyotrophic lateral sclerosis & frontotemporal degeneration. 2015;16(5-6):291-292.
47. Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al. Diagnostic criteria for 
amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and 
sensitivity. Clinical Neurophysiology. 2019;130(2):307-314.
48. Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for 
ALS. Clinical Neurophysiology. 2020;131(8):1975-1978.
49. Jayaprakash K, Glasmacher SA, Pang B, et al. Riluzole prescribing, uptake and 
treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland. 
Journal of neurology. 2020;267(8):2459-2461.
50. Newton J, Jayaprakash K, Glasmacher SA, et al. Excellent reliability of the ALSFRS-
R administered via videoconferencing: A study of people with motor neuron disease 
in Scotland. Journal of the Neurological Sciences. 2020;416.
Page 24 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
23
51. Franchignoni F, Mora G, Giordano A, Volanti P, Chiò A. Evidence of 
multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement 
properties using Rasch analysis. Journal of Neurology, Neurosurgery &amp; 
Psychiatry. 2013;84(12):1340-1345.
52. Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R 
really measure? A longitudinal and survival analysis of functional dimension 
subscores in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery 
&amp;amp; Psychiatry. 2017;88(5):381.
53. van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has 
overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS 
clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 
2021;22(3-4):300-307.
54. Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and 
reversals? Neurology. 2016;86(9):808-812.
55. Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical 
significance in the change of decline in ALSFRS-R. Amyotrophic lateral sclerosis : 
official publication of the World Federation of Neurology Research Group on Motor 
Neuron Diseases. 2010;11(1-2):178-180.
56. Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and 
predictive features. Neurology. 2014;83(19):1719-1725.
57. de Jonge JC, Reinink H, Colam B, et al. Regulatory delays in a multinational clinical 
stroke trial. European Stroke Journal. 2021;6(2):120-127.
58. Crow RA, Hart KA, McDermott MP, et al. A checklist for clinical trials in rare 
disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD 
trial. Trials. 2018;19(1):291.
59. ALS Association. AMX0035 petition delivered to FDA. 
https://www.als.org/blog/amx0035-petition-delivered-fda. Published 2021. Accessed.
60. Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG, Kish JK. Use of Real-
World Evidence to Support FDA Approval of Oncology Drugs. Value in Health. 
2020;23(10):1358-1365.
61. The Lancet N. Rapid drug access and scientific rigour: a delicate balance. The Lancet 
Neurology. 2021;20(1):1.
62. Collins R, Bowman L, Landray M, Peto R. The Magic of Randomization versus the 
Myth of Real-World Evidence. New England Journal of Medicine. 2020;382(7):674-
678.
63. OECD. Recommendation of the Council on the Governence of Clinical Trials. In. 
OECD/LEGAL/03972021.
64. Vesterinen HM, Connick P, Irvine CM, et al. Drug repurposing: a systematic 
approach to evaluate candidate oral neuroprotective interventions for secondary 
progressive multiple sclerosis. PloS one. 2015;10(4):e0117705.
65. Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSC-
derived neurons. Cell. 2011;145(6):831-834.
66. Sandoe J, Eggan K. Opportunities and challenges of pluripotent stem cell 
neurodegenerative disease models. Nature neuroscience. 2013;16(7):780-789.
67. Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 Trial of Antisense Oligonucleotide 
Tofersen for SOD1 ALS. New England Journal of Medicine. 2020;383(2):109-119.
68. TRICALS. TRICALS Phase 3 MAGNET trial. https://www.tricals.org/trials/magnet/. 
Accessed 10 November 2020.
69. Berry DA. Emerging innovations in clinical trial design. Clinical Pharmacology & 
Therapeutics. 2016;99(1):82-91.
Page 25 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
24
70. Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical 
trials: why use them, and how to run and report them. BMC Medicine. 2018;16(1):29.
71. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds 
insufficient evidence to justify phase III. Annals of neurology. 2009;66(2):235-244.
72. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic 
acid in amyotrophic lateral sclerosis. Annals of neurology. 2009;66(2):227-234.
73. Verstraete E, Veldink JH, Huisman MH, et al. Lithium lacks effect on survival in 
amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. Journal of 
neurology, neurosurgery, and psychiatry. 2012;83(5):557-564.
74. Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for 
amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-
controlled trial. Lancet Neurol. 2014;13(11):1083-1091.
75. Angus DC, Alexander BM, Berry S, et al. Adaptive platform trials: definition, design, 
conduct and reporting considerations. Nature Reviews Drug Discovery. 
2019;18(10):797-807.
76. Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority 
are needed. Lancet (London, England). 2014;384(9940):283-284.
77. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with 
Covid-19 — Preliminary Report. New England Journal of Medicine. 2020.
78. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not 
Previously Treated with Hormone Therapy. New England Journal of Medicine. 
2017;377(4):338-351.
79. James ND, Sydes MR, Clarke NW, et al. STAMPEDE: Systemic Therapy for 
Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised 
Controlled Trial. Clinical Oncology. 2008;20(8):577-581.
80. STAMPEDE. STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate 
cancer: Evaluation of Drug Efficacy. 2019.
81. Berry SM, Petzold EA, Dull P, et al. A response adaptive randomization platform trial 
for efficient evaluation of Ebola virus treatments: A model for pandemic response. 
Clinical Trials. 2016;13(1):22-30.
82. Hague D, Townsend S, Masters L, et al. Changing platforms without stopping the 
train: experiences of data management and data management systems when adapting 
platform protocols by adding and closing comparisons. Trials. 2019;20(1):294.
83. Morrell L, Hordern J, Brown L, et al. Mind the gap? The platform trial as a working 
environment. Trials. 2019;20(1):297.
84. Schiavone F, Bathia R, Letchemanan K, et al. This is a platform alteration: a trial 
management perspective on the operational aspects of adaptive and platform and 
umbrella protocols. Trials. 2019;20(1):264.
85. Sydes MR, Parmar MK, James ND, et al. Issues in applying multi-arm multi-stage 
methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials. 
2009;10:39.
86. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single 
protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage 
platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451-461.
87. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-
stage trials. Stat Methods Med Res. 2016;25(2):716-727.
88. Choodari-Oskooei B, Bratton DJ, Gannon MR, Meade AM, Sydes MR, Parmar MK. 
Adding new experimental arms to randomised clinical trials: Impact on error rates. 
Clin Trials. 2020;17(3):273-284.
Page 26 of 35
https://mc.manuscriptcentral.com/braincom









































































ick user on 26 O
ctober 2021
25
89. Saville B, Quintana M, Broglio K, et al. C8 The ALS platform trial: design 
considerations and statistical efficiencies. Amyotrophic lateral sclerosis & 
frontotemporal degeneration. 2019;20:7.
90. MND-SMART. MND-SMART Clinical trials for MND. www.mnd-smart.org. 
Accessed 3 February 2020.
91. The ALS Association. Epidemiology of ALS and Suspected Clusters. 
http://www.alsa.org/als-care/resources/publications-
videos/factsheets/epidemiology.html. Accessed 19 August 2019.
92. The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor 
neuron disease in Scotland. Methodology, demography and clinical features of 
incident cases in 1989. Journal of neurology, neurosurgery, and psychiatry. 
1992;55(7):536-541.
93. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J 
Neurol Sci. 2001;191(1-2):3-9.
94. Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor 
neuron disease in the United Kingdom: a population-based study. European journal 
of neurology. 2009;16(6):745-751.
Page 27 of 35
https://mc.manuscriptcentral.com/braincom













































































Figure 1 PRISMA diagram of systematic review. 
Figure 2 Number of people with ALS participating in trials. Figure 2A (top) shows number 
of pwALS recruited per trial by phase and year for trials with efficacy-based outcome 
measures. Published results were used as the source where available (denoted by circle), and 
registry data where unavailable (denoted by triangles). The ten trials with highest number of 
pwALS/trial are labelled with the intervention tested – these trials were two-arm trials with the 
exception of the following dose-ranging trials: tirasemtiv Phase III (4-arm), masitinib (3-arm), 
CK-2127107 (4-arm), talampanel (3-arm). The dashed horizontal lines reflect our sample size 
calculations using PROACT data: The red line indicates n = 200 (100/arm) required for a 2-
arm RCT with randomisation of 1:1, powered at 85% to detect a 25% difference in rate of 
ALSFRS-R decline over 12 months with a test conducted with a two-sided 20% significance 
level. The blue line indicates n = 500 (250/arm) required to evaluate one IMP in a two-arm 
RCT with randomisation of 1:1, powered of 90% to detect a hazard ratio of 0.65 for survival 
over 2 years with a two-sided 5% significance level. Figure 2B (bottom) shows a box and 
whiskers plot of the number of pwALS recruited per study arm according to CTIMP phase for 
Phase II (32 trials), Phase II/III (5 trials) and Phase III (12 trials) CTIMPs evaluating potential 
disease-modifying treatment of ALS.
Figure 3 Example sample size requirements according to trial designs.  3A: traditional 2-
arm Phase II trial with randomisation of 1:1 to evaluate 1 IMP against placebo or control with 
sample size calculated based on 85% power for a 20% two-sided significance level test to 
detect a 25% difference in rate of ALSFRS-R decline at 12 months calculated using data 
from PROACT56. 3B: a seamless phase II/phase III multi-arm multi-stage trial with 
randomisation of 1:1:1 with interim analysis where arms can be stopped if predefined 
efficacy and safety criteria are not met. 
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Table 1 Phase II, Phase II/III and Phase III CTIMP assessing potential disease modifying 
treatment in ALS registered, completed or published from 1 Jan 2008 onwards excluding 
extension trials according to status, phase and trial design.
Table 2 Novel trial designs for Phase II, Phase II/III and Phase III CTIMPs evaluating 
potential disease modifying treatment of ALS. *for multi-arm studies, trials specified 
evaluated more than one active investigational medicinal product; studies including 
concomitant use of riluzole and dose-ranging studies were not included here.
Table 3 Phase II, Phase II/III and Phase III CTIMP assessing potential disease modifying 
treatment in ALS registered, completed or published from 1 Jan 2008 onwards excluding 
extension trials according to type of primary outcome measure. AALSRS: Appel ALS Rating 
Scale; ALSFRS-R: ALS Functional Rating Scale Revised; ALS-MITOS: ALS Milano-Torino 
staging; CAFS: Combined Assessment of Function and Survival; CNS-BFS: Center of 
Neurologic Study Bulbar Function Scale; MMT: Manual Muscle Testing; SVC: Slow Vital 
Capacity.
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By status Number of trials
Active 35
Completed, has results 61
Completed, no results 12
















Assignment not specified: 1
96
Parallel, randomisation not specified 1
Not specified 2
Total 125
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NCT01257581: Phase II study comparing 
Creatine 30 mg vs Tamoxifen 40 mg vs 
Tamoxifen 80 mg
Y N N/A
NCT00355576: Phase II study comparing 




NCT00349622: Phase I-III study of 
ceftriaxone
Y Y N
Sequential / adaptive design 6
NTR 1448: Phase II study of lithium Y Y Y
NCT00136110: Phase III study of sodium 
valproate
Y Y Y
NCT00690118: Phase II study of 
pioglitazone
Y Y Y
NCT00243932: Phase II study of 
coenzyme Q10
Y Y Y
NCT00818389: Phase II/III study of 
lithium in combination with riluzole 
Y Y Y
NCT02238626: Ibudilast (MN-166) in 
Subjects with Amyotrophic Lateral 
Sclerosis (ALS) (IBU-ALS-1201)
N N/A N/A
Phase II Futility design 1
EudraCT 2014-005367-32: Phase II study 
of Guanabenz
N N/A N/A
Historical controls, primarily virtual data 
collection
1
NCT02709330: ALS Reversals – Lunasin 
Regimen
Y Y N/A
Adaptive Seamless Phase II/III 1
NCT00706147: Phase II/III Randomized, 
Placebo-controlled Trial of Arimoclomol 








Total 10 7/10 (70%) 5/7 (71%) 12
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Number of trialsType of primary outcome 
measure
Phase II Phase 
II/III
Phase III Total
Efficacy 63 8 18 89
Functional rating scales 39 4 8 51
ALSFRS-R 36 4 7 47
AALSRS 1 0 1 2
CNS-BFS 1 0 0 1
Penetration Aspiration Scale 1 0 0 1
Combined survival/functional 
outcome measure e.g. Joint rank 
scales/CAFS
1 1 2 4
Staging 3 1 0 4
ALS-MITOS 1 0 0 1
Loss of self-sufficiency 1 0 0 1
Time to tracheostomy/death 0 1 0 1
Not specified 1 0 0 1
Survival 8 1 6 15
Respiratory function (SVC) 2 0 1 3
Muscle strength 3 1 1 5
Manual Muscle Testing 
(MMT)
1 1 1 3
Isometric arm strength 2 0 0 2
Biomarkers 7 0 0 7
Cerebrospinal fluid 2 0 0 2
Blood 1 0 0 1
Neuroradiology 1 0 0 1
Neurophysiology 3 0 0 3
Pharmacodynamics / 
pharmacokinetics
4 0 0 4
Safety and tolerability 30 0 2 32
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Records not meeting 
criteria
(n = 683)
Inclusion criteria: Phase II, Phase II/III, Phase III Clinical Trial of Investigational Medicinal 
Product (CTIMP) assessing potential disease modifying treatment in Amyotrophic lateral 
sclerosis. Registered, completed or published from 1 Jan 2008 to 9 April 2019.
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pwALS/arm according to phase
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Number of participants 
























25% in the rate of 
decline
Rate of change in 
ALSFRS-R 
compared to 
placebo must be 
significant at a 
pairwise one-
sided 10% level. 
Power 90% power to 
detect 25% 
improvement in 
rate of change of 
ALSFRS-R
90% power to 
detect hazard 
ratio of 0.65 
Seamless Phase II / Phase III Multi-Arm Multi-Stage Trial
Placebo / Standard of careArm A
Phase II 2-arm Randomised Controlled Trial
Sample size required: 
95 participants/arm x 2 arm
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Clinical trials in Amyotrophic Lateral Sclerosis
















Lack of sensitive outcome measures and biomarkers
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Abbreviated summary
Wong et al. reviewed historical approaches to clinical trials in amyotrophic lateral sclerosis. Lack of 
sensitive outcome measures, limitations in resources and barriers to trial participation were challenges 
for timely and definitive evaluation of drugs in two-arm trials. They concluded that future trials 
should be more flexible, scalable and efficient.
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